CTNI-37. EFFICACY OF ONC201 IN PATIENTS WITH ONC201 FOR RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA

H3 K27M-mutant diffuse midline gliomas (DMG) have a dismal prognosis. We report an integrated analysis for ONC201, a DRD2 antagonist and ClpP agonist, in patients with recurrent H3 K27M DMG administered as monotherapy in 3 clinical studies (NCT03295396, n=20; NCT02525692, n=6; or expanded access, n=...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Neuro Oncol
Egile Nagusiak: Arrillaga-Romany, Isabel, Kurz, Sylvia, Tarapore, Rohinton S, Sumrall, Ashley, Butowski, Nicholas, Harrison, Rebecca, de Groot, John, Chi, Andrew, Shonka, Nicole, Umemura, Yoshie, Odia, Yazmin, Mehta, Minesh, Nghiemphu, Phioanh, Cloughesy, Timothy, Taylor, Lynne, Graber, Jerome, Kilburn, Lindsay, Dixit, Karan, Lu, Guangrong, Allen, Joshua, Batchelor, Tracy, Lassman, Andrew, Wen, Patrick
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2020
Gaiak:
Clinical Trials: Non-Immunologic
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651099/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.204
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak